2:18 PM
 | 
Dec 26, 2018
 |  BC Extra  |  Company News

FDA accepts Acer, Kala NDAs before funding lapse

Editor's Note: This article was updated on Dec 28, 2018 at 3:04 PM PST

FDA accepted for review NDAs from Acer Therapeutics Inc. (NASDAQ:ACER) and Kala Pharmaceuticals Inc. (NASDAQ:KALA) before the partial government shutdown blocked the agency from taking on new user fee-based applications.

The agency granted Priority Review to Acer's Edsivo celiprolol (ACER-002) to treat vascular Ehlers-Danlos syndrome (vEDS), a collagen production disorder. Its PDUFA date is June 25. Acer submitted the NDA using pivotal data that it licensed in 2016 from the Greater Paris...

Read the full 340 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >